Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: Evaluation of 27 polymorphisms within candidate genes

M. Postula, A. Kaplon-Cieslicka, M. Rosiak, A. Kondracka, A. Serafin, K. J. Filipiak, A. Czlonkowski, G. Opolski, Piotr Janicki

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Aims:Decreased platelet responsiveness to acetylsalicylic acid (ASA) reported previously in diabetic patients could be attributed to patient-based, clinical, genetic and cellular factors. The objective of the present study was to investigate the effect of the genomic polymorphism on the platelet reactivity in diabetic patients treated with ASA. Methods and results:The study cohort consisted of 295 Caucasians with diabetes type 2 who had been taking ASA tablets at the dose of 75mg per day for at least 3months for primary or secondary prevention of myocardial infarction (MI). Platelet reactivity analyzes were performed using VerifyNow ASA and PFA-100 assays. Genotyping for the selected 27 single nucleotide polymorphisms (SNPs) within 19 genes was performed using a Sequenom iPLEX platform. The results indicate that the statistically significant differences in platelet reactivity were observed in the PFA-100 assay for SNPs in following genes: TXBA2R (rs1131882), ADRA2A (rs4311994), PLA2G7 (rs7756935) and 9p21.3 (rs10120688) (P=0.02, P=0.03, P=0.02, P=0.03, respectively, all significance levels corrected for multiple comparisons). When using the VerifyNow ASA test, a weak nominal statistical significance (i.e. before multiple comparison testing) was observed for two SNPs in the GPVI gene: rs1671152 and rs1613662 [P=0.025 (0.5) for both SNPs, corrected for multiple comparisons test]. Conclusions:The results from the present study suggest that the four analyzed genes may contribute to platelet reactivity measured with the PFA-100 assay in the diabetic population treated with ASA.

Original languageEnglish (US)
Pages (from-to)2291-2301
Number of pages11
JournalJournal of Thrombosis and Haemostasis
Volume9
Issue number11
DOIs
StatePublished - Nov 1 2011

Fingerprint

Aspirin
Blood Platelets
Single Nucleotide Polymorphism
Genes
Therapeutics
Primary Prevention
Secondary Prevention
Type 2 Diabetes Mellitus
Tablets
Cohort Studies
Myocardial Infarction
Population

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Postula, M. ; Kaplon-Cieslicka, A. ; Rosiak, M. ; Kondracka, A. ; Serafin, A. ; Filipiak, K. J. ; Czlonkowski, A. ; Opolski, G. ; Janicki, Piotr. / Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients : Evaluation of 27 polymorphisms within candidate genes. In: Journal of Thrombosis and Haemostasis. 2011 ; Vol. 9, No. 11. pp. 2291-2301.
@article{dee6def17a864df0a05122e9e1949dc2,
title = "Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: Evaluation of 27 polymorphisms within candidate genes",
abstract = "Aims:Decreased platelet responsiveness to acetylsalicylic acid (ASA) reported previously in diabetic patients could be attributed to patient-based, clinical, genetic and cellular factors. The objective of the present study was to investigate the effect of the genomic polymorphism on the platelet reactivity in diabetic patients treated with ASA. Methods and results:The study cohort consisted of 295 Caucasians with diabetes type 2 who had been taking ASA tablets at the dose of 75mg per day for at least 3months for primary or secondary prevention of myocardial infarction (MI). Platelet reactivity analyzes were performed using VerifyNow ASA and PFA-100 assays. Genotyping for the selected 27 single nucleotide polymorphisms (SNPs) within 19 genes was performed using a Sequenom iPLEX platform. The results indicate that the statistically significant differences in platelet reactivity were observed in the PFA-100 assay for SNPs in following genes: TXBA2R (rs1131882), ADRA2A (rs4311994), PLA2G7 (rs7756935) and 9p21.3 (rs10120688) (P=0.02, P=0.03, P=0.02, P=0.03, respectively, all significance levels corrected for multiple comparisons). When using the VerifyNow ASA test, a weak nominal statistical significance (i.e. before multiple comparison testing) was observed for two SNPs in the GPVI gene: rs1671152 and rs1613662 [P=0.025 (0.5) for both SNPs, corrected for multiple comparisons test]. Conclusions:The results from the present study suggest that the four analyzed genes may contribute to platelet reactivity measured with the PFA-100 assay in the diabetic population treated with ASA.",
author = "M. Postula and A. Kaplon-Cieslicka and M. Rosiak and A. Kondracka and A. Serafin and Filipiak, {K. J.} and A. Czlonkowski and G. Opolski and Piotr Janicki",
year = "2011",
month = "11",
day = "1",
doi = "10.1111/j.1538-7836.2011.04482.x",
language = "English (US)",
volume = "9",
pages = "2291--2301",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "11",

}

Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients : Evaluation of 27 polymorphisms within candidate genes. / Postula, M.; Kaplon-Cieslicka, A.; Rosiak, M.; Kondracka, A.; Serafin, A.; Filipiak, K. J.; Czlonkowski, A.; Opolski, G.; Janicki, Piotr.

In: Journal of Thrombosis and Haemostasis, Vol. 9, No. 11, 01.11.2011, p. 2291-2301.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients

T2 - Evaluation of 27 polymorphisms within candidate genes

AU - Postula, M.

AU - Kaplon-Cieslicka, A.

AU - Rosiak, M.

AU - Kondracka, A.

AU - Serafin, A.

AU - Filipiak, K. J.

AU - Czlonkowski, A.

AU - Opolski, G.

AU - Janicki, Piotr

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Aims:Decreased platelet responsiveness to acetylsalicylic acid (ASA) reported previously in diabetic patients could be attributed to patient-based, clinical, genetic and cellular factors. The objective of the present study was to investigate the effect of the genomic polymorphism on the platelet reactivity in diabetic patients treated with ASA. Methods and results:The study cohort consisted of 295 Caucasians with diabetes type 2 who had been taking ASA tablets at the dose of 75mg per day for at least 3months for primary or secondary prevention of myocardial infarction (MI). Platelet reactivity analyzes were performed using VerifyNow ASA and PFA-100 assays. Genotyping for the selected 27 single nucleotide polymorphisms (SNPs) within 19 genes was performed using a Sequenom iPLEX platform. The results indicate that the statistically significant differences in platelet reactivity were observed in the PFA-100 assay for SNPs in following genes: TXBA2R (rs1131882), ADRA2A (rs4311994), PLA2G7 (rs7756935) and 9p21.3 (rs10120688) (P=0.02, P=0.03, P=0.02, P=0.03, respectively, all significance levels corrected for multiple comparisons). When using the VerifyNow ASA test, a weak nominal statistical significance (i.e. before multiple comparison testing) was observed for two SNPs in the GPVI gene: rs1671152 and rs1613662 [P=0.025 (0.5) for both SNPs, corrected for multiple comparisons test]. Conclusions:The results from the present study suggest that the four analyzed genes may contribute to platelet reactivity measured with the PFA-100 assay in the diabetic population treated with ASA.

AB - Aims:Decreased platelet responsiveness to acetylsalicylic acid (ASA) reported previously in diabetic patients could be attributed to patient-based, clinical, genetic and cellular factors. The objective of the present study was to investigate the effect of the genomic polymorphism on the platelet reactivity in diabetic patients treated with ASA. Methods and results:The study cohort consisted of 295 Caucasians with diabetes type 2 who had been taking ASA tablets at the dose of 75mg per day for at least 3months for primary or secondary prevention of myocardial infarction (MI). Platelet reactivity analyzes were performed using VerifyNow ASA and PFA-100 assays. Genotyping for the selected 27 single nucleotide polymorphisms (SNPs) within 19 genes was performed using a Sequenom iPLEX platform. The results indicate that the statistically significant differences in platelet reactivity were observed in the PFA-100 assay for SNPs in following genes: TXBA2R (rs1131882), ADRA2A (rs4311994), PLA2G7 (rs7756935) and 9p21.3 (rs10120688) (P=0.02, P=0.03, P=0.02, P=0.03, respectively, all significance levels corrected for multiple comparisons). When using the VerifyNow ASA test, a weak nominal statistical significance (i.e. before multiple comparison testing) was observed for two SNPs in the GPVI gene: rs1671152 and rs1613662 [P=0.025 (0.5) for both SNPs, corrected for multiple comparisons test]. Conclusions:The results from the present study suggest that the four analyzed genes may contribute to platelet reactivity measured with the PFA-100 assay in the diabetic population treated with ASA.

UR - http://www.scopus.com/inward/record.url?scp=80055116248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055116248&partnerID=8YFLogxK

U2 - 10.1111/j.1538-7836.2011.04482.x

DO - 10.1111/j.1538-7836.2011.04482.x

M3 - Article

C2 - 21854539

AN - SCOPUS:80055116248

VL - 9

SP - 2291

EP - 2301

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 11

ER -